BR9908267A - Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo - Google Patents
Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivoInfo
- Publication number
- BR9908267A BR9908267A BR9908267A BR9908267A BR9908267A BR 9908267 A BR9908267 A BR 9908267A BR 9908267 A BR9908267 A BR 9908267A BR 9908267 A BR9908267 A BR 9908267A BR 9908267 A BR9908267 A BR 9908267A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- individual against
- live attenuated
- immunize
- immunogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5421—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
"PLASMìDEO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA INDUZIR UMA RESPOSTA IMUNOLóGICA EM UM INDIVìDUO CONTRA UM IMUNóGENO, PARA IMUNIZAR UM INDIVìDUO CONTRA UMA INFECçãO POR VìRUS DE HERPES SIMPLES E PARA TRATAR UM INDIVìDUO QUE TEM UMA DOENçA AUTOIMUNE, VACINA RECOMBINANTE, E, PATóGENO ATENUADO VIVO". Descreve-se vacinas aperfeiçoadas que incluem uma seq³ência de nucleotídeos que codifica proteína imunomoduladora ligada operacionalmente a elementos reguladores. As vacinas aperfeiçoadas incluem vacinas de DNA, vacinas recombinantes para fornecer antígeno exógeno e vacinas vivas atenuadas. Descreve-se processos para imunizar indivíduos. Descreve-se composições e processos para o tratamento de indivíduos com doenças autoimunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7620798P | 1998-02-27 | 1998-02-27 | |
PCT/US1999/004332 WO1999043839A1 (en) | 1998-02-27 | 1999-02-26 | Vaccines, immunotherapeutics and methods for using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9908267A true BR9908267A (pt) | 2000-10-24 |
Family
ID=22130587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9908267A BR9908267A (pt) | 1998-02-27 | 1999-02-26 | Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo |
Country Status (12)
Country | Link |
---|---|
US (2) | US8119395B1 (pt) |
EP (1) | EP1078093B1 (pt) |
JP (3) | JP2002504380A (pt) |
KR (2) | KR20070039615A (pt) |
CN (1) | CN100352930C (pt) |
AT (1) | ATE512231T1 (pt) |
AU (1) | AU759603B2 (pt) |
BR (1) | BR9908267A (pt) |
CA (2) | CA2322160C (pt) |
IL (3) | IL138075A0 (pt) |
MX (1) | MXPA00008352A (pt) |
WO (1) | WO1999043839A1 (pt) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020136722A1 (en) * | 1997-06-18 | 2002-09-26 | Heath Andrew William | Vaccination method |
EP1078093B1 (en) | 1998-02-27 | 2011-06-08 | The Trustees of The University of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
SE9904863D0 (sv) * | 1999-12-30 | 1999-12-30 | Medscand Medical Ab | New use |
WO2001056602A2 (en) * | 2000-02-02 | 2001-08-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd40 ligand adjuvant for respiratory syncytial virus |
US20020022017A1 (en) * | 2000-04-12 | 2002-02-21 | Hua Yu | Regulation of systemic immune responses utilizing soluble CD40 |
AU2001253481A1 (en) * | 2000-04-21 | 2001-11-07 | Chemocentryx, Inc. | Methods and compositions for eleciting an immune response |
US7361329B2 (en) | 2000-04-21 | 2008-04-22 | Chemocentryx, Inc. | Compositions for inducing an immune response |
WO2001080882A2 (en) * | 2000-04-21 | 2001-11-01 | Chemocentryx, Inc | Methods and compositions for eliciting an immune response |
WO2001085209A2 (en) * | 2000-05-10 | 2001-11-15 | Eli Lilly And Company | Treating t-cell mediated diseases by modulating dr6 activity |
DK1282702T3 (da) | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
KR20090086452A (ko) * | 2000-05-12 | 2009-08-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 백신 및 이를 이용한 면역제 치료법 |
US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
CA2412436C (en) * | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
AU8349301A (en) | 2000-07-14 | 2002-01-30 | Univ Pennsylvania | Dna vaccines encoding hiv accessory proteins |
JP2004505113A (ja) * | 2000-07-27 | 2004-02-19 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 単純疱疹ウイルス糖蛋白質dを用いた組成物及びそれを用いて免疫応答を抑制する方法 |
AUPR524101A0 (en) | 2001-05-25 | 2001-06-21 | Council Of The Queensland Institute Of Medical Research, The | Antigen targeting |
WO2003035106A1 (en) * | 2001-10-24 | 2003-05-01 | Chemocentryx | Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
CN100542608C (zh) * | 2002-10-24 | 2009-09-23 | 株式会社Eci | 树突细胞前体的血中水平上升剂 |
WO2004050706A2 (en) * | 2002-12-03 | 2004-06-17 | Medical Research Council | Regulatory t-cells |
EP1667730B1 (en) * | 2003-08-20 | 2013-06-26 | University of Miami | Compositions and methods for treating inflammatory lung disease |
CN101124327A (zh) | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
JP4696079B2 (ja) | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Aβ免疫原性ペプチド担体結合物およびそれの製造方法 |
SG149013A1 (en) | 2003-12-17 | 2009-01-29 | Wyeth Corp | Immunogenic peptide carrier conjugates and methods of producing same |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
US20060121031A1 (en) | 2004-12-07 | 2006-06-08 | Mckenzie Brent S | Relay vaccine |
ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
AU2007239095B2 (en) * | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
WO2007082105A2 (en) | 2006-01-16 | 2007-07-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chlamydia vaccine |
EP3255141B1 (en) | 2006-07-13 | 2021-12-01 | Wyeth LLC | Production of antibodies with improved glycosylation pattern |
US8192951B2 (en) | 2006-11-03 | 2012-06-05 | Wyeth Llc | Glycolysis-inhibiting substances in cell culture |
DK2115126T3 (en) | 2007-03-02 | 2015-05-04 | Wyeth Llc | Use of copper and glutamate in cell culture for the preparation of polypeptides |
WO2010062904A2 (en) | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性t細胞のinvivoにおける増殖 |
WO2011079070A1 (en) | 2009-12-23 | 2011-06-30 | Gradalis, Inc. | Furin-knockdown bi-functional rna |
CN102917709B (zh) | 2009-12-23 | 2018-04-24 | 格兰达利斯有限公司 | 弗林蛋白酶敲减和gm-csf增强的(fang)癌症疫苗 |
JP5388971B2 (ja) | 2010-08-24 | 2014-01-15 | 住友重機械工業株式会社 | 減速装置 |
CN108126204A (zh) * | 2011-03-11 | 2018-06-08 | 特斯通有限责任合伙公司 | 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法 |
AU2013292617A1 (en) | 2012-07-19 | 2015-01-22 | Zoetis Llc | Bovine influenza C virus compositions |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
WO2014110258A1 (en) | 2013-01-09 | 2014-07-17 | Podack Eckhard R | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
US20160008449A1 (en) | 2013-03-15 | 2016-01-14 | Zoetis Services Llc | CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE |
JP6555687B2 (ja) * | 2013-11-20 | 2019-08-07 | 国立大学法人北海道大学 | 免疫制御剤 |
PL3334454T3 (pl) | 2015-08-14 | 2023-01-30 | Zoetis Services Llc | Kompozycje mycoplasma bovis |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
KR102637862B1 (ko) | 2017-12-13 | 2024-02-19 | 이노비오 파마수티컬즈, 인크. | 메소텔린을 표적으로 하는 암 백신 및 이의 용도 |
CN110464841B (zh) * | 2019-08-19 | 2020-05-22 | 启辰生生物科技(珠海)有限公司 | 免疫增强的药物组合物及其应用 |
BR112022014417A2 (pt) | 2020-01-24 | 2022-09-13 | Pfizer | Anticorpos anti-e-selectina, composições e métodos de uso |
CN113005072A (zh) * | 2021-04-09 | 2021-06-22 | 佛山科学技术学院 | 一种马链球菌兽疫亚种基因缺失株及其制备方法和应用 |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
WO1990010693A1 (en) | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
WO1990011687A1 (en) | 1989-03-31 | 1990-10-18 | Washington University | VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS |
EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
WO1992015672A1 (en) * | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
JPH05276986A (ja) * | 1992-04-02 | 1993-10-26 | Sumitomo Electric Ind Ltd | 単球遊走性サイトカインに対する抗体 |
JP3519096B2 (ja) * | 1992-07-02 | 2004-04-12 | 武田薬品工業株式会社 | モノクローナル抗体、ハイブリドーマおよびそれらの用途 |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
US5990301A (en) * | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP0712632A1 (en) * | 1994-04-08 | 1996-05-22 | Toray Industries, Inc. | Remedy for diseases characterized by abnormal accumulation or activation of leukocyte |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
ATE197765T1 (de) * | 1994-10-03 | 2000-12-15 | Us Gov Health & Human Serv | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
CA2201592A1 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
PT811073E (pt) | 1995-02-24 | 2007-03-30 | Univ Pennsylvania | Utilização de moduladores imunitários para preparar medicamentos que inibem as respostas imunitárias contra vírus recombinantes co-administrados |
US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
JPH0930973A (ja) * | 1995-07-19 | 1997-02-04 | Toray Ind Inc | 腎炎治療もしくは予防薬 |
JPH0967399A (ja) * | 1995-08-30 | 1997-03-11 | Mitsui Toatsu Chem Inc | 抗mcp−1ヒトモノクローナル抗体 |
US5916879A (en) * | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
WO1999009165A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
EP1078093B1 (en) | 1998-02-27 | 2011-06-08 | The Trustees of The University of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
-
1999
- 1999-02-26 EP EP99936096A patent/EP1078093B1/en not_active Expired - Lifetime
- 1999-02-26 AU AU33130/99A patent/AU759603B2/en not_active Ceased
- 1999-02-26 KR KR1020077005921A patent/KR20070039615A/ko active Search and Examination
- 1999-02-26 KR KR1020007009514A patent/KR100743894B1/ko not_active IP Right Cessation
- 1999-02-26 BR BR9908267A patent/BR9908267A/pt not_active IP Right Cessation
- 1999-02-26 JP JP2000533578A patent/JP2002504380A/ja active Pending
- 1999-02-26 IL IL13807599A patent/IL138075A0/xx unknown
- 1999-02-26 CN CNB998031828A patent/CN100352930C/zh not_active Expired - Fee Related
- 1999-02-26 CA CA 2322160 patent/CA2322160C/en not_active Expired - Fee Related
- 1999-02-26 MX MXPA00008352A patent/MXPA00008352A/es not_active IP Right Cessation
- 1999-02-26 US US09/622,452 patent/US8119395B1/en not_active Expired - Fee Related
- 1999-02-26 WO PCT/US1999/004332 patent/WO1999043839A1/en active Application Filing
- 1999-02-26 AT AT99936096T patent/ATE512231T1/de not_active IP Right Cessation
- 1999-02-26 CA CA 2792479 patent/CA2792479A1/en not_active Abandoned
-
2000
- 2000-08-24 IL IL138075A patent/IL138075A/en not_active IP Right Cessation
-
2009
- 2009-07-09 JP JP2009162877A patent/JP5485601B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-23 JP JP2010037428A patent/JP2010187672A/ja active Pending
-
2012
- 2012-01-27 US US13/360,389 patent/US20130045180A9/en not_active Abandoned
- 2012-06-03 IL IL220133A patent/IL220133A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20130045180A9 (en) | 2013-02-21 |
KR20010082517A (ko) | 2001-08-30 |
CA2792479A1 (en) | 1999-09-02 |
EP1078093A1 (en) | 2001-02-28 |
CA2322160A1 (en) | 1999-09-02 |
WO1999043839A1 (en) | 1999-09-02 |
AU759603B2 (en) | 2003-04-17 |
KR20070039615A (ko) | 2007-04-12 |
EP1078093B1 (en) | 2011-06-08 |
US8119395B1 (en) | 2012-02-21 |
CN1291235A (zh) | 2001-04-11 |
JP2002504380A (ja) | 2002-02-12 |
JP2009263396A (ja) | 2009-11-12 |
IL138075A0 (en) | 2001-10-31 |
KR100743894B1 (ko) | 2007-07-30 |
IL138075A (en) | 2012-08-30 |
IL220133A0 (en) | 2012-07-31 |
ATE512231T1 (de) | 2011-06-15 |
EP1078093A4 (en) | 2001-12-05 |
JP2010187672A (ja) | 2010-09-02 |
AU3313099A (en) | 1999-09-15 |
US20120195852A1 (en) | 2012-08-02 |
CN100352930C (zh) | 2007-12-05 |
CA2322160C (en) | 2013-01-29 |
MXPA00008352A (es) | 2002-10-17 |
JP5485601B2 (ja) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9908267A (pt) | Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo | |
Morein et al. | Current status and potential application of ISCOMs in veterinary medicine | |
Minke et al. | Equine viral vaccines: the past, present and future | |
WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
BR0316758A (pt) | Vacinas baseadas em levedura como imunoterapia | |
EA016648B1 (ru) | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии | |
AU2016271144B2 (en) | Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases | |
YU102103A (sh) | Mycoplasma bovis vakcina i postupci redukovanja pneumonije kod životinja | |
US8632781B2 (en) | Immunogenic compounds comprising peptides of IL1β | |
BR0010155A (pt) | Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo | |
Roque-Resendiz et al. | MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis | |
Wang et al. | A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus | |
Yoon et al. | Cytokine GM‐CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses | |
Cañas‐Arranz et al. | A bivalent B‐cell epitope dendrimer peptide can confer long‐lasting immunity in swine against foot‐and‐mouth disease | |
Lodmell et al. | Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody | |
Pack et al. | Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with herpes simplex virus | |
Belyakov et al. | Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host | |
Tudor et al. | Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C | |
Dory et al. | CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
RU2660566C2 (ru) | Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген | |
Sanicas et al. | A review of COVID-19 vaccines in development: 6 months into the pandemic | |
Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice | |
Kammer et al. | Rabies vaccines: from the past to the 21st century | |
KR102553857B1 (ko) | 신규 핵산 분자 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 17A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |